In a Phase 3 trial, drugmaker Eli Lilly and Company said it’s oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.
In a Phase 3 trial, drugmaker Eli Lilly and Company said it’s oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.